Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Rifaximin

Rifaximin

pharmaceutical raw materials
Rifaximin structure

Rifaximin 

structure
  • CAS No:

    80621-81-4

  • Formula:

    C43H51N3O11

  • Chemical Name:

    Rifaximin

  • Synonyms:

    2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-;2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,[2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]-;(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione;L 105;Rifamycin L 105SV;L 105SV;Rifaximin;Rifamycin L 105;L 105 (ansamacrolide antibiotic);refaximin;Xifaxan;Normix;Xifaxanta;(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23,25-Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-acetate;126334-60-9;88747-56-2;1229193-76-3

  • Categories:

    Active Pharmaceutical Ingredients  >  Antibiotics

Description

Rifaximin(Xifaxan) is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity.IC50 Value:Target: RNA polymerase; antibacterialRifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used in the treatment of traveler's diarrhea and hepatic encephalopat


Rifaximin is a nonabsorbable antibiotic that is used as treatment and prevention of travelers’ diarrhea and, in higher doses, for prevention of hepatic encephalopathy in patients with advanced liver disease and to treat diarrhea in patients with irritable bowel syndrome. Rifaximin has minimal oral absorption and has not been implicated in causing liver test abnormalities or clinically apparent liver injury.|A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.

Rifaximin Basic Attributes

785.88

785.88

1308068-626-2

DTXSID7045998

A - Alimentary tract and metabolism|D - Dermatologicals

Characteristics

198

6.29580

dark orange

1.4±0.1 g/cm3

200-205 °C (decomp)

1.634

ethanol: soluble1mg/mL

0-6°C

LD50 orally in rats: >2000 mg/kg (Borelli, Bertoli)

Safety Information

NONH for all modes of transport

2

KD1576000

|Warning|H312 (76.92%): Harmful in contact with skin [Warning Acute toxicity, dermal]|P201, P202, P261, P271, P280, P281, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 17 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Despite widespread use, there is little evidence that rifaximin when given orally causes liver injury, either in the form of serum enzyme elevations or clinically apparent liver disease.

Drug Information

Rifaximin is a nonabsorbable antibiotic that is used as treatment and prevention of travelers’ diarrhea and, in higher doses, for prevention of hepatic encephalopathy in patients with advanced liver disease and to treat diarrhea in patients with irritable bowel syndrome. Rifaximin has minimal oral absorption and has not been implicated in causing liver test abnormalities or clinically apparent liver injury.

Antiinfective Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)|Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)

4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin

Rifaximin Use and Manufacturing

Uses

Non-absorbable semisynthetic Rifamycin antibiotic

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:785.9
XLogP3:6.9
Hydrogen Bond Donor Count:5
Hydrogen Bond Acceptor Count:12
Rotatable Bond Count:3
Exact Mass:785.35235945
Monoisotopic Mass:785.35235945
Topological Polar Surface Area:198
Heavy Atom Count:57
Complexity:1590
Defined Atom Stereocenter Count:9
Undefined Bond Stereocenter Count:3
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This product is a derivative of rifamycin and is the first non-aminoglycoside intestinal antibiotic. This product has a strong effect and a broad antibacterial spectrum. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. This product has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. When using this product, there is no need to use intestinal antispasmodics (such as lopramamide, etc.) or intestinal adsorbents (such as white clay, pectin, etc.). This product acts quickly, and diarrhea will no longer occur after 2 days, and abdominal cramps, headaches, nausea, and vomiting symptoms will disappear quickly. This product is not absorbed and maintains extremely high concentrations in the intestine, but does not exist in other organs. Features superior to neomycin, streptomycin and other aminoglycoside antibiotics: ① This product does not damage hearing function; ② It does not cause renal damage; ③ Parasitic normal flora, especially non-pathogenic enteric bacteria Escherichia coli, quickly relocate to the intestines to avoid repeated infection; ④ Intestinal mucosal inflammation may tend to disappear. Mucosal inflammation is a contraindication to the use of topical aminoglycosides, because the inflammation may be aggravated after medication.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • CHEMECA DRUGS PRIVATE LTD

    United States United States
    Active
  • OPTIMUS DRUGS PRIVATE LTD

    United States United States
    Active
  • RAKS PHARMA PVT LTD

    United States United States
    Active

Recommended Suppliers of Rifaximin

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.